Recall report: Acella pulls thyroid tablets after a raft of side effect reports; mislabeling causes Pfizer's Hospira to yank 2 lots of anesthetics
Acella Pharmaceuticals has pulled its NP Thyroid tablets off US shelves after routine testing found different versions of the drug not hitting potency marks. In this case, that screw-up had an immediate effect on patients with 43 reports of serious side effects, the FDA said.
The 38 recalled lots contained less than 90% of their labeled amount of liothyronine and levothyroxine, the FDA said. Of those lots, 35 of them were 100-count bottles of either 15mg, 120mg, 30mg, 60mg or 90 mg tablets. Another three were seven-count bottles of 15mg, 30mg and 120mg tablets.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.